Navigation Links
Arpida's iclaprim MAA Accepted for Review by EMEA
Date:8/21/2008

REINACH, Switzerland, August 21 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that the European Medicines Agency (EMEA) has accepted for review its Marketing Authorisation Application (MAA) for intravenous iclaprim. Arpida is seeking approval of intravenous iclaprim in the European Union for the treatment of complicated Skin and Soft Tissue Infections (cSSTI). Iclaprim is a hospital antibiotic drug candidate with potent bactericidal (killing) activity against MRSA and an extended range of important pathogens.

The iclaprim MAA contains data from 15 clinical studies, including two well-controlled multinational pivotal Phase III trials (ASSIST-1 and ASSIST-2, in which approximately 1,000 patients were treated). Patients enrolled in the Phase III trials exhibited a high incidence of methicillin-resistant Staphylococcus aureus (MRSA) as causative pathogen. In both of these two independent Phase III trials, intravenous iclaprim achieved the pre-specified primary endpoint of non-inferiority as compared to linezolid. In the studies, iclaprim was well-tolerated with a safety profile which compared favourably with the comparator in the treatment of patients with cSSTI.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "Iclaprim is under regulatory review at the major health authorities on both sides of the Atlantic. We are steadily continuing our progress towards our goal of launching intravenous iclaprim, thereby providing healthcare professionals with a new option in treating serious skin infections."

In addition to the cSSTI indication, intravenous iclaprim is also being developed for the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens. This programme is currently in Phase II clinical evaluation. Moreover, an oral formulation of iclaprim is currently in a Phase
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
2. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
3. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
4. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
7. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
8. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
9. Neuralstem Shares Accepted for Trading on Amex(R)
10. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
11. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... CAMBRIDGE, England , July 29, 2014 ... das Liquid Biopsy System (LBS) zur Erfassung ... an den Herzkranzgefäßen entwickelt und patentiert. Das ... Stellen innerhalb der Koronararterie des Patienten und ... Das LBS hat das Potenzial, die Entdeckung ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 According ... Transparency Market Research "Regenerative Medicine (Bone and Joint) ... and Tissue Engineering; By Applications - Bone Graft ... Others) - Global Industry Analysis, Size, Share, Growth, ... regenerative medicine (bone and joint) market was valued ...
(Date:7/28/2014)... 2014  David Hardison, Ph.D., vice president of ... has been elected chairman of the board for ... working to establish common protocols around the use ... to electronic health records. Hardison ... with organizations across the research and health care ...
(Date:7/28/2014)... The global market for biotechnology is expected ... a new study by Grand View Research, Inc. Increasing ... vaccines and drugs in an attempt to improve healthcare ... to drive market demand over the next six years. ... the use of genetically engineered seeds is expected to ...
Breaking Biology Technology:PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... Oct. 17 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ... 2007 financial results on Wednesday, October 24,2007 after the ... a,conference call at 5:00 p.m. ET, which will be ... conference call, the company will review,the financial results and ...
... ST. LOUIS, Oct. 17 Monsanto Company (NYSE:,MON) ... Hugh Grant,chairman, president and chief executive officer, and ... have established stock trading,plans in accordance with Rule ... Under these plans, the Monsanto executives have directed ...
... today that,the Henry C. Witelson Ocular Pathology Laboratory ... Personal Archive biosample management system.,The laboratory is located ... a critical component of the Laboratory,s,research in determining ... and retinoblastoma and for developing new approaches for,treatment. ...
Cached Biology Technology:Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast 2McGill University Purchases GenVault's Personal Archive System to Manage Rare Cancer Samples 2
(Date:7/28/2014)... himself the bug hunter, but the target of his ... and identified with special methods and instruments. Benjamin Hause, ... Diagnostic Laboratory at Kansas State University, recently published an ... which is an important find in the United States. ... didn,t know what it was," Hause said. "We used ...
(Date:7/28/2014)... , July 28, 2014 Research and ... "Biometrics Market in Latin America 2014-2018" report to ... Biometrics measure and analyze biological data. These ... irises, eye retinas, voice patterns, and hand measurements from ... more stored templates. The main purpose of a biometrics ...
(Date:7/28/2014)... Norwegian explorer Roald Amundsen became the first man ... More than 100 years later, an international team of ... Institute (DRI) have proven that air pollution from industrial ... ice cores collected from widely spaced locations around the ... the most accurate and precise reconstruction to date of ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... Chinese hybrid rice genome, which was published in the Journal ... map of the rice genome. In an article published by ... scientists led by the Beijing Institute of Genomics (BIG) reported ... japonica subspecies of O. sativa." , The fine maps of ...
... an important molecular signaling mechanism whose existence has been,known, ... since the,identification of a mutant strain of Drosophila fruit ... Later studies,revealed that the Notch gene encodes a receptor ... and which is capable of,interacting with a ligand partner, ...
... new research indicates that it may all come down ... University scientists who had previously identified a key gene ... now shows that this gene's function appears to be ... by Leslie Vosshall's laboratory had previously shown that of ...
Cached Biology News:Whole genome fine map of rice completed 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3Ancient olfaction protein is shared by many bugs, offering new pest control target 2
... 3B8A10. Immunogen: Recombinant ... C-terminal region of human ... for the human ubiquilin ... (positive control: 293 cells). ...
...
...
... I-96 Plate can be used either in ... large-scale (i.e., 96-well) purification of DNA and/or ... unique silica-based matrix make it perfect for ... RNA in = 10 l eluate per ...
Biology Products: